Cargando…

Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma

Dendritic cells (DCs) are the most potent antigen-presenting cells, and have thus been used in clinical cancer vaccines. However, the effects of DC vaccines are still limited, leading researchers to explore novel ways to make them effective. In this study, we investigated whether human monocyte-deri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Tan-Huy, Vo, Manh-Cuong, Lakshmi, Thangaraj Jaya, Ahn, Seo-Yeon, Kim, Mihee, Song, Ga-Young, Yang, Deok-Hwan, Ahn, Jae-Sook, Kim, Hyeoung-Joon, Jung, Sung-Hoon, Lee, Je-Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006865/ https://www.ncbi.nlm.nih.gov/pubmed/35413499 http://dx.doi.org/10.1016/j.tranon.2022.101413

Ejemplares similares

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
por: Thangaraj, Jaya Lakshmi, et al.
Publicado: (2022)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
por: Hoang, My-Dung, et al.
Publicado: (2015)

Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2019)

Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells
por: Vo, Manh-Cuong, et al.
Publicado: (2017)

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen
por: Kim, Su-In, et al.
Publicado: (2022)

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
por: Song, Ga-Young, et al.
Publicado: (2020)

Cellular immunotherapy using dendritic cells against multiple myeloma
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
por: Nguyen-Pham, Thanh-Nhan, et al.
Publicado: (2012)

Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment
por: Jung, Sung-Hoon, et al.
Publicado: (2015)

The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2014)

Sarcoplasmic reticulum Ca(2+) ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells
por: Hong, Cheol Yi, et al.
Publicado: (2016)

STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2017)

Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma
por: Kim, Mihee, et al.
Publicado: (2021)

Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)

Next‐generation sequencing‐based analysis to assess the pattern of relapse in patients with Philadelphia‐positive acute lymphoblastic leukemia
por: Ahn, Jae‐Sook, et al.
Publicado: (2022)

Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells
por: Hoang, My-Dung, et al.
Publicado: (2015)

P1194: PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS
por: Song, Ga-Young, et al.
Publicado: (2023)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
por: Yang, Deok-Hwan, et al.
Publicado: (2015)

Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2015)

Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
por: Park, Hyung-Chul, et al.
Publicado: (2012)

Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
por: Jung, Sung-Hoon, et al.
Publicado: (2012)

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
por: Ahn, Seo-Yeon, et al.
Publicado: (2023)

Newly Developed Multiple Myeloma in a Patient with Primary T-Cell Lymphoma of Bone
por: Hwang, Jun-Eul, et al.
Publicado: (2008)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo
por: Mai, Thi Thao, et al.
Publicado: (2021)

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
por: Kim, Therasa, et al.
Publicado: (2018)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
por: Tran, Huong Thi Thanh, et al.
Publicado: (2011)

FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
por: Ahn, Jae-Sook, et al.
Publicado: (2022)

Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1c86lltojgshkbaumcfd086gh2